Chimeric virus technology (CVT) for HIV env-genes to evaluate the resistance/susceptibility profile towards HIV entry inhibitors

Fikkert; Peter Cherepanov; Kristel Van Laethem; Anke Hantson; Barbara Van Remoortel; Christophe Pannecouque; De Clercq Erik; Zeger Debyser; Anne‐Mieke Vandamme; Myriam Witvrouw

Related publications

Article2002

env Chimeric Virus Technology for Evaluating Human Immunodeficiency Virus Susceptibility to Entry Inhibitors

Valery Fikkert, Peter Cherepanov, Kristel Van Laethem, Anke Hantson, Barbara Van Remoortel, Christophe Pannecouque, De Clercq Erik, Zeger Debyser, Anne‐Mieke Vandamme, Myriam Witvrouw

Article2003

env Chimeric Virus Technology for Evaluating Human Immunodeficiency Virus Susceptibility to Entry Inhibitors

Valery Fikkert, Peter Cherepanov, Kristel Van Laethem, Anke Hantson, Barbara Van Remoortel, Christophe Pannecouque, De Clercq Erik, Zeger Debyser, Anne‐Mieke Vandamme, Myriam Witvrouw

Article2005

Mutations in Bothenvandgaggenes are required for HIV-1 resistance to the polysulfonic dendrimer SPL2923, as corroborated by chimeric virus technology

Anke Hantson, Valery Fikkert, Barbara Van Remoortel, Christophe Pannecouque, Peter Cherepanov, Barry Matthews, George Holan, De Clercq Erik, Anne‐Mieke Vandamme, Zeger Debyser, Myriam Witvrouw

Article2003

Construction of chimeric feline immunodeficiency virus reverse transcriptase to map its lack of susceptibility to non-nucleoside reverse transcriptase inhibitors

Johan Auwerx, Robert Esnouf, De Clercq Erik, Jan Balzarini

Article2005

Resistance profile of human immunodeficiency virus to CADA, a novel HIV inhibitor that targets the cellular CD4 receptor

Kurt Vermeire, Kristel Van Laethem, Anne‐Mieke Vandamme, Thomas W. Bell, De Clercq Erik, Dominique Schols

Chimeric virus technology (CVT) for HIV env-genes to evaluate the resistance/susceptibility profile towards HIV entry inhibitors

Discussion(0)

Related publications

<i>env</i> Chimeric Virus Technology for Evaluating Human Immunodeficiency Virus Susceptibility to Entry Inhibitors

<i>env</i> Chimeric Virus Technology for Evaluating Human Immunodeficiency Virus Susceptibility to Entry Inhibitors

Mutations in Both<i>env</i>and<i>gag</i>genes are required for HIV-1 resistance to the polysulfonic dendrimer SPL2923, as corroborated by chimeric virus technology

Construction of chimeric feline immunodeficiency virus reverse transcriptase to map its lack of susceptibility to non-nucleoside reverse transcriptase inhibitors

Resistance profile of human immunodeficiency virus to CADA, a novel HIV inhibitor that targets the cellular CD4 receptor